RTC
IRWD icon

Riverview Trust Company’s Ironwood Pharmaceuticals IRWD Stock Holding History

Riverview Trust Company’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-154
Closed -$682 – 720
2024
Q4 		$682 Buy
+154
New +$625 ﹤0.01% 715

Other funds holding IRWD

SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Riverview Trust Company's IRWD Position: Q1 2025 in Review

Riverview Trust Company sold out of Ironwood Pharmaceuticals (IRWD) in Q1 2025, closing a stake of 154 shares — an estimated $682 sold.

Riverview Trust Company first reported a position in IRWD in Q4 2024 and held it in 1 quarter. The position peaked at $682 in Q4 2024. 200 funds tracked by Wall St. Rank hold IRWD as of Q1 2025.

  • Riverview Trust Company reported no remaining Ironwood Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Riverview Trust Company sold 154 Ironwood Pharmaceuticals shares in Q1 2025, an estimated $682.
  • Riverview Trust Company first reported a position in Ironwood Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Riverview Trust Company's Ironwood Pharmaceuticals position peaked at $682 in Q4 2024.
  • 200 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2025.

Based on Riverview Trust Company's 13F filing for Q1 2025, filed 11 Apr 2025.